The mission of the Lombardi Cancer Center (LCC) is to provide expert and humanitarian care to cancer patients, their families, and those at risk, and to bring an increased understanding of the cellular and molecular biology of the malignant process and the individual's and society's response to it. The Cancer Center Support Grant (CCSG) is critical to that mission. This proposal is a renewal application for years 14 to 18 of the CCSG for the LCC of Georgetown University (GU). Since the establishment of the LCC in December 1970, GU has maintained a high level of commitment to the success of the cancer center. In the present application, the LCC is represented by 156 members, participating in seven research programs with 11 shared resources, working primarily in two adjacent buildings. Peer reviewed research funding for FY02 totals $36.9 million. In FY02, the LCC clinical services served more than 3,500 new cancer patients and 21,000 outpatient cancer visits, and more than 600 patients were enrolled on LCC clinical trials. The LCC has seen significant changes, which have improved the center's ability to fulfill its stated mission: 1) In 1999, an academic Department of Oncology was created by GU, significantly strengthening authority and effectiveness of the LCC Director by facilitating faculty recruitment and the enhancement of research programs. 2) In 2000, GU Hospital became part of MedStar Health, a non-profit network of seven regional hospitals, which together see more than 7000 new cancer patients annually. This affiliation has significantly strengthened both clinical activity and clinical research at LCC. 3) On September 3, 2002, Richard G. Pestell, MBBS, MD, PhD, an internationally renowned researcher in cell cycle regulation, was appointed LCC Director. The success of the cancer center's research environment is demonstrated in its three basic science programs, two clinical translational programs, and two population based prevention and control programs. With CCSG support and guided by its external and internal advisory committees, the LCC has developed and maintained an outstanding interdisciplinary team of basic, population-based and clinical researchers who are committed to high quality and clinically relevant cancer research. We seek continued CCSG support as the only comprehensive cancer center in the Nation's Capital.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA051008-15S2
Application #
7122185
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1990-09-30
Project End
2007-04-30
Budget Start
2005-05-01
Budget End
2006-04-30
Support Year
15
Fiscal Year
2005
Total Cost
$36,742
Indirect Cost
Name
Georgetown University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Lee, Yichien; Rodriguez, Olga C; Albanese, Chris et al. (2018) Divergent brain changes in two audiogenic rat strains: A voxel-based morphometry and diffusion tensor imaging comparison of the genetically epilepsy prone rat (GEPR-3) and the Wistar Audiogenic Rat (WAR). Neurobiol Dis 111:80-90
Coia, Heidi; Ma, Ning; Hou, Yanqi et al. (2018) Prevention of Lipid Peroxidation-derived Cyclic DNA Adduct and Mutation in High-Fat Diet-induced Hepatocarcinogenesis by Theaphenon E. Cancer Prev Res (Phila) 11:665-676
Ory, Virginie; Kietzman, William B; Boeckelman, Jacob et al. (2018) The PPAR? agonist efatutazone delays invasive progression and induces differentiation of ductal carcinoma in situ. Breast Cancer Res Treat 169:47-57
Ozawa, Patricia Midori Murobushi; Alkhilaiwi, Faris; Cavalli, Iglenir João et al. (2018) Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. Breast Cancer Res Treat 172:713-723
Smith, Jill P; Wang, Shangzi; Nadella, Sandeep et al. (2018) Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice. Cancer Immunol Immunother 67:195-207
Edwardson, Matthew A; Zhong, Xiaogang; Fiandaca, Massimo S et al. (2018) Plasma microRNA markers of upper limb recovery following human stroke. Sci Rep 8:12558
Kaat, Aaron J; Schalet, Benjamin D; Rutsohn, Joshua et al. (2018) Physical function metric over measure: An illustration with the Patient-Reported Outcomes Measurement Information System (PROMIS) and the Functional Assessment of Cancer Therapy (FACT). Cancer 124:153-160
Maximov, Philipp Y; Abderrahman, Balkees; Fanning, Sean W et al. (2018) Endoxifen, 4-Hydroxytamoxifen and an Estrogenic Derivative Modulate Estrogen Receptor Complex Mediated Apoptosis in Breast Cancer. Mol Pharmacol 94:812-822
Czarnecka, Magdalena; Lu, Congyi; Pons, Jennifer et al. (2018) Neuropeptide Y receptor interactions regulate its mitogenic activity. Neuropeptides :
Gonzalez, Thomas L; Moos, Rebecca K; Gersch, Christina L et al. (2018) Metabolites of n-Butylparaben and iso-Butylparaben Exhibit Estrogenic Properties in MCF-7 and T47D Human Breast Cancer Cell Lines. Toxicol Sci 164:50-59

Showing the most recent 10 out of 1120 publications